Da‐Qiang Li

9.9k total citations · 4 hit papers
87 papers, 4.5k citations indexed

About

Da‐Qiang Li is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Da‐Qiang Li has authored 87 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 25 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Da‐Qiang Li's work include Ubiquitin and proteasome pathways (17 papers), RNA modifications and cancer (15 papers) and DNA Repair Mechanisms (12 papers). Da‐Qiang Li is often cited by papers focused on Ubiquitin and proteasome pathways (17 papers), RNA modifications and cancer (15 papers) and DNA Repair Mechanisms (12 papers). Da‐Qiang Li collaborates with scholars based in China, United States and Laos. Da‐Qiang Li's co-authors include Rakesh Kumar, Yi‐Zhou Jiang, Xi Jin, Xin Hu, Ding Ma, Zhi‐Ming Shao, Sujit S. Nair, Yi Xiao, Gen‐Hong Di and Jia-Han Ding and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Da‐Qiang Li

83 papers receiving 4.5k citations

Hit Papers

Ferroptosis heterogeneity in triple-negative breast cance... 2020 2026 2022 2024 2022 2020 2022 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy
    2022 383 citations Xi Jin, Ding Ma et al. profile →
  2. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
    2020 296 citations Yue Gong, Yun‐Song Yang et al. profile →
  3. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer
    2022 275 citations Yi Xiao, Ding Ma et al. profile →
  4. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
    2022 202 citations Yi Xiao, Yun‐Song Yang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Da‐Qiang Li China 35 3.1k 1.2k 1.1k 731 454 87 4.5k
Sunmin Lee United States 30 2.7k 0.9× 1.3k 1.1× 724 0.6× 741 1.0× 260 0.6× 63 4.3k
Gary R. Fanger United States 31 2.5k 0.8× 769 0.6× 954 0.9× 800 1.1× 328 0.7× 55 4.0k
Juliane M. Jürgensmeier United States 30 3.7k 1.2× 738 0.6× 1.3k 1.1× 533 0.7× 269 0.6× 69 5.4k
John Brognard United States 25 3.7k 1.2× 658 0.5× 1.0k 0.9× 464 0.6× 332 0.7× 50 4.5k
Kazuya Shinmura Japan 37 3.1k 1.0× 1.1k 0.9× 1.2k 1.0× 691 0.9× 395 0.9× 142 4.6k
Sang‐Gu Hwang South Korea 38 2.4k 0.8× 826 0.7× 913 0.8× 325 0.4× 450 1.0× 123 3.9k
Sophie Vacher France 39 2.6k 0.8× 1.5k 1.2× 1.5k 1.3× 587 0.8× 412 0.9× 142 4.5k
Ádám Nagy Hungary 17 2.8k 0.9× 1.5k 1.2× 1000 0.9× 980 1.3× 250 0.6× 28 4.0k
Kiyotsugu Yoshida Japan 40 4.0k 1.3× 859 0.7× 1.5k 1.4× 276 0.4× 439 1.0× 108 5.4k
Chih‐Yang Wang Taiwan 32 2.3k 0.7× 1.1k 0.9× 1.1k 1.0× 672 0.9× 261 0.6× 108 3.6k

Countries citing papers authored by Da‐Qiang Li

Since Specialization
Citations

This map shows the geographic impact of Da‐Qiang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Da‐Qiang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Da‐Qiang Li more than expected).

Fields of papers citing papers by Da‐Qiang Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Da‐Qiang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Da‐Qiang Li. The network helps show where Da‐Qiang Li may publish in the future.

Co-authorship network of co-authors of Da‐Qiang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Da‐Qiang Li. A scholar is included among the top collaborators of Da‐Qiang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Da‐Qiang Li. Da‐Qiang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Da‐Qiang, et al.. (2025). Autophagy-Related Proteins in Triple-Negative Breast Cancer: From Molecular Insights to Therapeutic Applications. International Journal of Molecular Sciences. 26(18). 9231–9231.
3.
4.
5.
6.
Deng, Ling, Li Liao, Shu‐Yuan Hu, et al.. (2024). SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1. Science Advances. 10(14). eadj4009–eadj4009. 28 indexed citations
7.
8.
Liao, Li, Ling Deng, Xiao-Yan Ma, et al.. (2022). Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer. Cancer Research. 83(3). 471–484. 43 indexed citations
9.
Wei, Jinli, Siyu Wu, Yun‐Song Yang, et al.. (2021). GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 9(7). e002383–e002383. 41 indexed citations
10.
Liang, Ying, Lu Qi, Wei Li, et al.. (2021). Reactivation of tumour suppressor in breast cancer by enhancer switching through NamiRNA network. Nucleic Acids Research. 49(15). 8556–8572. 42 indexed citations
11.
Wu, Siyu, Yi Xiao, Jinli Wei, et al.. (2021). MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. Journal for ImmunoTherapy of Cancer. 9(7). e002528–e002528. 62 indexed citations
12.
Ma, Ding, Siyu Chen, Yu‐Chen Pei, et al.. (2020). Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. 113(7). 884–892. 28 indexed citations
13.
Zheng, Yi-Zi, Hongjie Shen, Ding Ma, et al.. (2018). PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Research. 78(12). 3190–3206. 65 indexed citations
14.
15.
Sun, Rui, et al.. (2018). FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression. Cancer Research. 78(18). 5274–5286. 83 indexed citations
16.
17.
Nair, Sujit S., Da‐Qiang Li, & Rakesh Kumar. (2013). A Core Chromatin Remodeling Factor Instructs Global Chromatin Signaling through Multivalent Reading of Nucleosome Codes. Molecular Cell. 49(4). 704–718. 58 indexed citations
18.
Eswaran, Jeyanthy, et al.. (2012). Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations. Clinical Cancer Research. 18(14). 3743–3749. 65 indexed citations
19.
Li, Da‐Qiang, Sujit S. Nair, Kazufumi Ohshiro, et al.. (2012). MORC2 Signaling Integrates Phosphorylation-Dependent, ATPase-Coupled Chromatin Remodeling during the DNA Damage Response. Cell Reports. 2(6). 1657–1669. 110 indexed citations
20.
Miao, Hui, Da‐Qiang Li, Amitava Mukherjee, et al.. (2009). EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt. Cancer Cell. 16(1). 9–20. 412 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sunmin Lee Breakdown of academic impact, for papers by Gary R. Fanger Breakdown of academic impact, for papers by Juliane M. Jürgensmeier Breakdown of academic impact, for papers by John Brognard Breakdown of academic impact, for papers by Kazuya Shinmura Breakdown of academic impact, for papers by Sang‐Gu Hwang Breakdown of academic impact, for papers by Sophie Vacher Breakdown of academic impact, for papers by Ádám Nagy Breakdown of academic impact, for papers by Kiyotsugu Yoshida Breakdown of academic impact, for papers by Chih‐Yang Wang
Rankless by CCL
2026